Followers | 4053 |
Posts | 151260 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Tuesday, April 11, 2017 8:33:07 AM
GlobeNewswire-April 11, 2017
-- Milestone payment received with completion of IND-enabling toxicology studies --
-- Catalyst’s collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017 --
SOUTH SAN FRANCISCO, Calif., April 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a key milestone under its collaboration with ISU Abxis to advance the Factor IX program towards its first human clinical trial. Completion of the CB 2679d/ISU304 toxicology studies supported the recent Investigational New Drug (IND) approval by the Korean Ministry of Food and Drug Safety (MFDS) and triggered a milestone payment to Catalyst.
CB 2679d/ISU304, a highly potent next-generation coagulation Factor IX variant, has demonstrated the potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. Currently approved therapies rely on frequent intravenous infusions where adherence is difficult and convenient access to peripheral veins is a problem, often requiring the use of central venous access devices with the associated risks of infection and thrombosis. Catalyst’s collaborator, ISU Abxis (086890.KQ), plans to initiate a Phase 1/2 proof-of-concept study with single and multiple subcutaneous injections in individuals with severe hemophilia B in the second quarter of 2017.
“Individuals with severe hemophilia B will experience abnormal bleeding - not just after an injury, but spontaneously into potentially any organ, joints or muscles. Without preventative treatment or prophylaxis, these individuals may experience several spontaneous bleeding episodes per month,” said Nassim Usman, Ph.D., President and Chief Executive Officer of Catalyst. “Our vision is to prevent bleeding with the stabilization and normalization of clotting levels using more convenient subcutaneous dosing.”
Catalyst has a collaboration with ISU Abxis to advance the development of CB 2679d/ISU304 through a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B. After Phase 1/2, ISU Abxis has an option for exclusive commercial rights in South Korea and a profit share on ex-South Korean commercialization. Catalyst retains full development and commercial rights for CB 2679d/ISU304 outside of South Korea. Under the license agreement, the next potential milestone payment is for the first patient enrolled in the Phase 1/2 trial.
About Factor IX
CB 2679d/ISU304 is a next-generation coagulation Factor IX variant that is IND-approved in South Korea. Catalyst believes that CB 2679d/ISU304 may allow for subcutaneous prophylactic treatment of individuals with hemophilia B. Learn more about Factor IX.
About Hemophilia and Factor Replacement Therapy
Hemophilia, for which there is no cure, is a rare but serious bleeding disorder that results from a genetic or an acquired deficiency of a protein required for normal blood coagulation. Individuals with hemophilia suffer from spontaneous bleeding episodes as well as substantially prolonged bleeding times upon injury. Learn more about hemophilia.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Recent CBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2024 10:19:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2024 08:51:43 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2024 12:49:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2024 12:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2024 12:46:38 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/19/2024 08:06:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/09/2024 08:31:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/08/2024 10:03:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/05/2024 09:40:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/04/2024 09:27:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/03/2024 08:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2024 08:01:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2024 09:35:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2024 10:42:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 09:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2024 01:55:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:31:12 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/22/2024 12:27:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/21/2024 11:15:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2024 08:47:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/15/2024 09:29:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:16:03 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:11:14 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/19/2024 09:05:30 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/12/2024 09:01:35 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM